Literature DB >> 26432836

Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L.

Chengli Song1, Qiang Xu1, Kui Jiang1, Guangyu Zhou1, Xuebin Yu1, Lina Wang1, Yuting Zhu1, Liping Fang1, Zhe Yu1, Jiing-Dwan Lee2, Shi-Cang Yu3, Qingkai Yang1.   

Abstract

Cancer stem cells (CSCs) possess many characteristics associated with stem cells and are believed to drive tumor initiation. Although targeting of CSCs offers great promise for the new generation of therapeutics, lack of the effective drugable target and appropriate pharmacological reagents significantly impedes the development of chemotherapies. Here, we show that the phosphorylation of BMK1 was significantly correlated with not only embryonic and induced pluripotent stem (iPS) cells, but also the CSCs. It was showed that activation of BMK1 by the expression of MEK5D enhanced the self-renew (sphere formation), proliferation (clone formation) and tumorigenic capacity of CSCs. While BMK1 inhibitor, XMD8-92, suppressed these capacities. RNA-seq and microarray analysis revealed that inhibition of BMK1 significantly enhanced the expression of BNIP3 and BNIP3L, which play important roles in cell death. Further study indicated that shRNA-mediated knock down of BNIP3 and BNIP3L impairs the BMK1 inhibitor, XMD8-92-induced suppression of sphere formation and clone formation of CSC. Collectively, these results not only indicate that BMK1 plays an important role in maintaining "stemness" of CSCs, but also implicate that BMK1 might be a potential drug target for CSCs.

Entities:  

Keywords:  BMK1; cancer stem cell; kinase

Mesh:

Substances:

Year:  2015        PMID: 26432836      PMCID: PMC4741765          DOI: 10.18632/oncotarget.5337

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  36 in total

1.  Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.

Authors:  Tzipora Shoshani; Alexander Faerman; Igor Mett; Elena Zelin; Tamar Tenne; Svetlana Gorodin; Yana Moshel; Shlomo Elbaz; Andrei Budanov; Ayelet Chajut; Hagar Kalinski; Iris Kamer; Ada Rozen; Orna Mor; Eli Keshet; Dena Leshkowitz; Paz Einat; Rami Skaliter; Elena Feinstein
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

Authors:  Azucena Esparís-Ogando; Elena Díaz-Rodríguez; Juan Carlos Montero; Laura Yuste; Piero Crespo; Atanasio Pandiella
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

3.  HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.

Authors:  Barbara Chiavarina; Diana Whitaker-Menezes; Gemma Migneco; Ubaldo E Martinez-Outschoorn; Stephanos Pavlides; Anthony Howell; Herbert B Tanowitz; Mathew C Casimiro; Chenguang Wang; Richard G Pestell; Philip Grieshaber; Jaime Caro; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-09-04       Impact factor: 4.534

4.  The ERK5 and ERK1/2 signaling pathways play opposing regulatory roles during chondrogenesis of adult human bone marrow-derived multipotent progenitor cells.

Authors:  Brent E Bobick; Alexander I Matsche; Faye H Chen; Rocky S Tuan
Journal:  J Cell Physiol       Date:  2010-07       Impact factor: 6.384

5.  Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

Authors:  Qingkai Yang; Xianming Deng; Bingwen Lu; Michael Cameron; Colleen Fearns; Matthew P Patricelli; John R Yates; Nathanael S Gray; Jiing-Dwan Lee
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

6.  Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia.

Authors:  R K Bruick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

7.  Targeting the BMK1 MAP kinase pathway in cancer therapy.

Authors:  Qingkai Yang; Jiing-Dwan Lee
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

8.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

Authors:  Yin Wang; Yan Liu; Sami N Malek; Pan Zheng; Yang Liu
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

9.  Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.

Authors:  Christopher B Weldon; Ali B Scandurro; Kevin W Rolfe; John L Clayton; Steven Elliott; Nancy N Butler; Lilia I Melnik; Jawed Alam; John A McLachlan; Bernard M Jaffe; Barbara S Beckman; Matthew E Burow
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

10.  Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.

Authors:  J Lai; J Flanagan; W A Phillips; G Chenevix-Trench; J Arnold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

View more
  5 in total

Review 1.  Oncogenic signaling of MEK5-ERK5.

Authors:  Van T Hoang; Thomas J Yan; Jane E Cavanaugh; Patrick T Flaherty; Barbara S Beckman; Matthew E Burow
Journal:  Cancer Lett       Date:  2017-01-30       Impact factor: 8.679

2.  ERK5 kinase activity is dispensable for cellular immune response and proliferation.

Authors:  Emme C K Lin; Christopher M Amantea; Tyzoon K Nomanbhoy; Helge Weissig; Junichi Ishiyama; Yi Hu; Shyama Sidique; Bei Li; John W Kozarich; Jonathan S Rosenblum
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-27       Impact factor: 11.205

3.  Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma.

Authors:  Chengli Song; Lina Wang; Qiang Xu; Kai Wang; Dan Xie; Zhe Yu; Kui Jiang; Lujian Liao; John R Yates; Jiing-Dwan Lee; Qingkai Yang
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

4.  ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer.

Authors:  Van T Hoang; Margarite D Matossian; Deniz A Ucar; Steven Elliott; Jacqueline La; Maryl K Wright; Hope E Burks; Aaron Perles; Fokhrul Hossain; Connor T King; Valentino E Browning; Jacob Bursavich; Fang Fang; Luis Del Valle; Akshita B Bhatt; Jane E Cavanaugh; Patrick T Flaherty; Muralidharan Anbalagan; Brian G Rowan; Melyssa R Bratton; Kenneth P Nephew; Lucio Miele; Bridgette M Collins-Burow; Elizabeth C Martin; Matthew E Burow
Journal:  Front Oncol       Date:  2020-08-03       Impact factor: 6.244

5.  IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC.

Authors:  Qiang Xu; Kai Wang; Lina Wang; Yuting Zhu; Guangyu Zhou; Dan Xie; Qingkai Yang
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.